Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

Adcentrx Therapeutics Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ADRX-0706, a groundbreaking Antibody-Drug Conjugate (ADC) that targets Nectin-4 to treat advanced solid tumors. This marks the first time that Adcentrx's ADC platform has been granted FDA clearance, signaling a major milestone for the company. ..